Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Versantis AG

Versantis is a clinical-stage biotech company focused on the development of orphan drugs in liver diseases and pediatric inborn errors of metabolism. Founded by leading scientists from ETH Zurich and industry experts, Versantis is pursuing innovative therapies for the acute care of serious liver conditions based on its proprietary liposomes-based detoxification platform technology. Its lead candidate, VS-01, uses a disruptive route to enhance the clearance of ammonia and other toxins from the body. The company’s mission is to bring therapeutic solutions to many patients in need by timely supporting acute decompensations of cirrhosis (Versantis’ most advanced program) as well as rare hyperammonemic genetic disorders in children. VS-01 is currently being evaluated in first-in-human clinical trials, with outcomes expected mid-2020. VS-01 was granted orphan drug designations in acute liver failure by the EMA and in ACLF by the FDA, which will streamline its clinical development pathway. Versantis is headquartered in Zurich, Switzerland. *


Period Start 2015-03-01 established (s-off)
  Predecessor ETH Zürich (ETHZ)
Products Industry VS-01 (Versantis)
  Industry 2 drug development
Persons Person Forster, Vincent (Versantis AG 201704 CEO + Co-Founder)
  Person 2 Kabbaj, Meriam (Versantis AG 201704 COO + Co-Founder)
Region Region Zürich ZH
  Country Switzerland
  Street 1 Technoparkstr.
Technopark Zürich, Newton Wing 3007, 3rd Floor
  City 8005 Zürich ZH
  Tel +41-44-500-8891
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Versantis AG. (9/18/19). "Press Release: Versantis Closes CHF 16M Series B Financing Round to Advance Clinical Development of Novel Therapeutics for Liver Diseases". Zürich.
Record changed: 2020-10-22


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for Versantis AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top